ImmunityBio, Inc. Common Stock
Veridion Score
Composite trend over time
Why is IBRX moving today?
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IBRX.
IBRX insider activity
ImmunityBio, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for IBRX.
IBRX contract awards, year to date.
Public federal awards linked to this ticker.
IBRX lobbying filings, year to date.
Registered lobbying filings matched to ImmunityBio, Inc. Common Stock.